Trial Profile
Phase 3 Study of Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for Prevention of Excessive Bleeding in Congenital Hemophilia A/B Patients With Inhibitors to Factor VIII/IX Undergoing Elective Surgery/Other Invasive Procedures
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jul 2022
Price :
$35
*
At a glance
- Drugs Recombinant factor VIIa (Primary)
- Indications Haemophilia A; Haemorrhage
- Focus Therapeutic Use
- Acronyms PERSEPT 3
- 15 Jul 2022 According to LFB media release, the European Medicines Agency (EMA) has granted a Marketing Authorisation for CEVENFACTA (eptacog beta) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures, based on data from PERSEPT 1 and PERSEPT 3 studies.
- 01 Nov 2021 Results from three Phase 3 trials (PERSEPT 1, PERSEPT 2 and PERSEPT 3) assessing the EB safety, immunogenicity and thrombotic potential in children and adults who received EB for treatment of bleeding and perioperative care, published in the Haemophilia.
- 01 Nov 2021 Results published in the Haemophilia